

# CITATION REPORT

List of articles citing

## Oral complications of targeted cancer therapies: a narrative literature review

DOI: 10.1016/j.oraloncology.2011.03.028  
Oral Oncology, 2011, 47, 441-8.

**Source:** <https://exaly.com/paper-pdf/51087490/citation-report.pdf>

**Version:** 2024-04-19

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
103	Potential Therapeutic Roles for Inhibition of the PI3K/Akt/mTOR Pathway in the Pathophysiology of Diabetic Retinopathy. <b>2011</b> , 2011, 589813		54
102	Bevacizumab-induced oral mucositis in background of cutaneous plaque-type psoriasis. <b>2012</b> , 46, e32		3
101	Characteristics of oral mucosal events related to bevacizumab treatment. <b>2012</b> , 17, 274-8		20
100	New developments in management of oral mucositis in patients with head and neck cancer or receiving targeted anticancer therapies. <b>2012</b> , 69, 1031-7		16
99	Xerostomia: dall'etiologia al trattamento. <b>2012</b> , 80, 568-594		1
98	The risk of skin rash and stomatitis with the mammalian target of rapamycin inhibitor temsirolimus: a systematic review of the literature and meta-analysis. <b>2012</b> , 48, 340-6		40
97	Oral complications of cancer and cancer therapy: from cancer treatment to survivorship. <b>2012</b> , 62, 400-22		252
96	Dental students' knowledge of characteristics and management of oral complications of cancer therapy. <b>2013</b> , 21, 2793-8		5
95	Risk of oral and gastrointestinal mucosal injury among patients receiving selected targeted agents: a meta-analysis. <b>2013</b> , 21, 3243-54		37
94	Osteonecrosis of the mandible associated with bevacizumab therapy. <b>2013</b> , 115, e32-6		53
93	Oral ulcers in patients with advanced breast cancer receiving everolimus: a case series report on clinical presentation and management. <b>2013</b> , 116, e110-6		20
92	Potential implications of adjuvant endocrine therapy for the oral health of postmenopausal women with breast cancer. <b>2013</b> , 137, 23-32		11
91	Personalized medicine: predicting the risk of complications of cancer therapy. <b>2013</b> , 19, 633-4		1
90	SAMITAL <sup>®</sup> : a new botanical drug for the treatment of mucositis induced by oncological therapies. <b>2013</b> , 9, 1717-25		7
89	In reply. <b>2013</b> , 18, e18		2
88	Cancer. <b>2013</b> , 204-217		1
87	Mammalian target of rapamycin inhibitor-associated stomatitis. <b>2013</b> , 9, 1883-92		61

86	Efficacy of HPA Lanolin in treatment of lip alterations related to chemotherapy. <b>2013</b> , 21, 163-6	2
85	Oral toxicity produced by chemotherapy: A systematic review. <b>2014</b> , 6, e81-90	49
84	[Managing patients with therapeutic antibodies in odontostomatology]. <b>2014</b> , 115, 152-63	2
83	Appropriate and necessary oral care for people with cancer: guidance to obtain the right oral and dental care at the right time. <b>2014</b> , 22, 1981-8	31
82	Side effects and complications of cancer and its treatment. <b>2014</b> , 53-184	1
81	Cutaneous manifestations of anti-angiogenic therapy in oncology: Review with focus on VEGF inhibitors. <b>2014</b> , 90, 152-64	39
80	Oral Mucosal Injury in Oncology Patients. <b>2014</b> , 1, 190-195	
79	[Oral toxicity of targeted anticancer therapies]. <b>2014</b> , 141, 354-63	10
78	Patient-reported outcomes for immediate identification of dental care needs. <b>2015</b> , 6, 1-7	
77	Orofacial adverse effects of biological agents. <b>2015</b> , 6, 252-60	8
76	Dermatologic adverse events in pediatric patients receiving targeted anticancer therapies: a pooled analysis. <b>2015</b> , 62, 798-806	22
75	Management of oral and gastrointestinal mucosal injury: ESMO Clinical Practice Guidelines for diagnosis, treatment, and follow-up. <b>2015</b> , 26 Suppl 5, v139-51	115
74	Mechanism-based management for mucositis: option for treating side effects without compromising the efficacy of cancer therapy. <b>2016</b> , 9, 2007-16	42
73	Oral and dental health in head and neck cancer survivors. <b>2016</b> , 1, 14	14
72	[Chronic or recurrent ulceration of the tongue]. <b>2016</b> , 143, 297-308; quiz 295-6, 309-10	
71	Low-level laser therapy/photobiomodulation in the management of side effects of chemoradiation therapy in head and neck cancer: part 2: proposed applications and treatment protocols. <b>2016</b> , 24, 2793-805	126
70	Pigmentation of the Tongue with Lapatinib Treatment in a Patient with Advanced Breast Cancer: A Case Report. <b>2016</b> , 7, 1-3	3
69	Management of chemo/radiation-induced oral mucositis in patients with head and neck cancer: A review of the current literature. <b>2016</b> , 120, 13-20	66

68	Oral mucosal injury caused by mammalian target of rapamycin inhibitors: emerging perspectives on pathobiology and impact on clinical practice. <b>2016</b> , 5, 1897-907	51
67	Toxicities associated with head and neck cancer treatment and oncology-related clinical trials. <b>2016</b> , 40, 244-257	10
66	Luteolin Impacts on the DNA Damage Pathway in Oral Squamous Cell Carcinoma. <b>2016</b> , 68, 838-47	15
65	Low level laser therapy/photobiomodulation in the management of side effects of chemoradiation therapy in head and neck cancer: part 1: mechanisms of action, dosimetric, and safety considerations. <b>2016</b> , 24, 2781-92	116
64	Understanding the impact of taste changes in oncology care. <b>2016</b> , 24, 1917-31	42
63	Oral mucosal changes induced by anticancer targeted therapies and immune checkpoint inhibitors. <b>2017</b> , 25, 1713-1739	82
62	Everolimus-related adverse events in neuroendocrine tumors and comparative considerations with breast and renal cancer: a critical overview. <b>2017</b> , 5, 525-536	
61	Insight in taste alterations during treatment with protein kinase inhibitors. <b>2017</b> , 86, 125-134	19
60	Protocolo de manejo de la mucositis en el paciente oncológico. <b>2017</b> , 12, 1929-1933	
59	Oral Complications of Nonsurgical Cancer Therapies. <b>2017</b> , 25, 133-147	17
58	Imatinib. <b>2017</b> , 97-122	1
57	Sorafenib. <b>2017</b> , 167-197	
56	Targeted cancer therapies: Oral health care implications. <b>2018</b> , 149, 100-111	7
55	Oral stomatitis and mTOR inhibitors: A review of current evidence in 20,915 patients. <b>2018</b> , 24, 144-171	12
54	Dental Management of Patients Who Have Undergone Oral Cancer Therapy. <b>2018</b> , 62, 131-142	22
53	Photobiomodulation or low-level laser therapy in the management of cancer therapy-induced mucositis, dermatitis and lymphedema. <b>2018</b> , 30, 226-232	32
52	Oral/Dental Oncology. <b>2018</b> , 341-366	2
51	Potential cytotoxic and selective effect of new benzo[b]xanthenes against oral squamous cell carcinoma. <b>2018</b> , 10, 1141-1157	5

50	Oral Mucosal Injury Caused by Targeted Cancer Therapies. <b>2019</b> , 2019,	5
49	Drugs and Dysphagia. <b>2019</b> , 111-126	1
48	Prevalence of oral side effects of chemotherapy and its relationship with periodontal risk: a cross sectional study. <b>2019</b> , 27, 3479-3490	8
47	Transplant oncology: assessment of response and tolerance to systemic chemotherapy for metastatic colorectal cancer after liver transplantation - a retrospective study. <b>2019</b> , 32, 1144-1150	11
46	Oral mucosal changes associated with primary diseases in other body systems. <b>2019</b> , 80, 28-48	9
45	A rare case of bevacizumab-related osteonecrosis of the jaw associated with dental implants. <b>2019</b> , 5, 34	4
44	Oral health and chemotherapy act as cofactors in malnutrition in the elderly with other cancers than head and neck malignancies. <b>2019</b> , 23, 235-243	5
43	Oral Complications. <b>2020</b> , 607-620.e6	
42	Dental Practice Patterns for Oral Care in Medical Oncology Patients-a Survey-Based Assessment of Massachusetts Dentists. <b>2020</b> , 1	1
41	Chemotherapy and dysphagia: the good, the bad, the ugly. <b>2020</b> , 28, 385-391	3
40	Severe chronic nonlichenoid oral mucositis in pembrolizumab-treated patients: new cases and a review of the literature. <b>2020</b> , 12, 777-784	3
39	Oral management strategies for radiotherapy of head and neck cancer. <b>2020</b> , 56, 62-67	24
38	The impact of hematological malignancies and their treatment on oral health-related quality of life as assessed by the OHIP-14: a systematic review. <b>2020</b> , 108, 511-520	1
37	Conclusion: Drug-Induced Oral Complications. <b>2021</b> , 121-122	
36	GI Toxicities from Cancer Therapy. <b>2021</b> , 341-379	
35	Management of Patients under Treatment with Monoclonal Antibodies and New Biological Therapies. <b>2021</b> , 11, 4865	0
34	Transplantation Medicine. <b>2021</b> , 745-783	0
33	Risk factors for dysgeusia during chemotherapy for solid tumors: a retrospective cross-sectional study. <b>2022</b> , 30, 313-325	1

32	Oral Complications of Head and Neck Cancer Therapy. <b>2021</b> , 12, 52-66	0
31	Oral Complications. <b>2014</b> , 635-647.e4	3
30	Effect of dihydropyrrrol and maleimide derivatives on the state of the liver and colon in normal rats and those with colorectal carcinogenesis induced by dimethylhydrazine. <b>2013</b> , 85, 74-84	14
29	Review of the complications associated with treatment of oropharyngeal cancer: a guide for the dental practitioner. <b>2013</b> , 44, 267-79	15
28	Alterations in Taste and Smell. <b>2012</b> , 271-294	
27	A Prospective Study on Adverse Drug Reactions in an Indian Hospital.	
26	Bidirectional Associations Between Oral and Systemic Health. <b>2014</b> , 65-82	
25	Impacts and Interrelationships Between Medications, Nutrition, Dietary Supplements, and Oral Health. <b>2014</b> , 83-107	
24	Pigmentation palatine associée à un traitement par imatinib. <b>2014</b> , 20, 275-277	
23	Oral complications of radiotherapy: approaches to prevention and treatment. <b>2015</b> , 96, 397-400	1
22	Toxicité orales des thérapies ciblées anticancéreuses. <b>2015</b> , 21, 149-155	2
21	Oral Manifestation of Gastrointestinal Diseases. 2459-2469	
20	Orofacial Pain in Cancer. <b>2017</b> , 21-32	0
19	Oral Health and Survivorship: Late Effects of Cancer and Cancer Therapy. <b>2018</b> , 653-664	0
18	GI Toxicities from Cancer Therapy. <b>2020</b> , 1-39	
17	Molecularly targeted drugs for the treatment of cancer: oral complications and pathophysiology. <b>2012</b> , 16, 196-9	14
16	Oral health-related complications of breast cancer treatment: assessing dental hygienists' knowledge and professional practice. <b>2014</b> , 88, 100-13	1
15	Oral Health-Related Complications of Breast Cancer Treatment: Assessing Dental Hygienists' Knowledge and Professional Practice. <b>2015</b> , 89 Suppl 2, 22-37	0

14	Unusual and Interesting Adverse Cutaneous Drug Reactions. <b>2018</b> , 63, 107-116	
13	Late Oral Complications Caused by Head and Neck Radiotherapy: Clinical and Laboratory Study. <b>2020</b> , 11, e3	1
12	Late Oral Complications Caused by Head and Neck Radiotherapy: Clinical and Laboratory Study. <b>2020</b> , 11, e3	1
11	Oral Mucositis. <b>2022</b> , 49-97	1
10	Photobiomodulation and Light Therapy in Oncology. <b>2022</b> , 255-286	
9	Strategies to mitigate the toxicity of cancer therapeutics. <b>2022</b> ,	0
8	Active Health Governance-A Conceptual Framework Based on a Narrative Literature Review.. <b>2022</b> , 19,	0
7	Occurrence of Dysgeusia in Patients Being Treated for Cancer.. <b>2022</b> , 1-7	0
6	Propranolol inhibits cell viability and expression of the pro-tumorigenic proteins Akt, NF- $\kappa$ B, and VEGF in oral squamous cell carcinoma.. <b>2022</b> , 136, 105383	1
5	Mitigating acute chemotherapy-associated adverse events in patients with cancer. <b>2022</b> , 19, 681-697	0
4	The Role of the Restorative Dentist in the Management of Head and Neck Cancer Patients. <b>2023</b> , 91-97	0
3	Sunitinib promotes apoptosis via p38 MAPK activation and STAT3 downregulation in oral keratinocytes.	0
2	Oral Side Effects in Patients with Metastatic Renal Cell Carcinoma Receiving the Antiangiogenic Agent Pazopanib Report of Three Cases. <b>2022</b> , 10, 232	0
1	Chemotherapy-Induced Oral Complications and Prophylaxis Strategies. 1-24	0